Natco Pharma share price extended gains for a fourth straight session on Wednesday, February 25, surging as much as 11.45% to hit an intraday high of ₹990 on the National Stock Exchange (NSE).
The rally followed regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India.
Earlier this month, Natco Pharma announced that it had received approval from CDSCO to manufacture and market generic Semaglutide in India. The Hyderabad-based drug maker said it plans to launch the product in March 2026.
The approval is seen as a significant milestone, given the growing demand for diabetes and weight management therapies in India. The development has triggered strong investor interest, driving the stock sharply higher in recent sessions.
In a parallel development, Eris Lifesciences announced a strategic partnership with Natco Pharma for the commercialisation of Semaglutide in India. The collaboration is expected to leverage Eris’ marketing strength and distribution network, enhancing the product’s reach across domestic markets.
Analysts believe the partnership could accelerate market penetration and boost revenue visibility once the product is launched.
Semaglutide, a GLP-1 receptor agonist, has emerged as a breakthrough therapy for Type 2 diabetes and chronic weight management. It works by stimulating insulin release, reducing glucagon secretion, and slowing gastric emptying, while also curbing appetite and calorie intake.
Globally, the semaglutide market is projected to grow significantly, with IQVIA estimating its value between $34 billion and $47 billion during 2025–2032. Popular global brands such as Ozempic and Wegovy are currently priced between ₹8,800 and ₹16,400 per month in India.
With regulatory approval secured, analysts expect Natco Pharma to launch its generic version at a more affordable price, potentially expanding access to treatment.
Read more: Will Your Mobile Bills Rise? TRAI’s Spectrum Price Cut Explained.
The CDSCO approval and strategic partnership mark a pivotal growth trigger for Natco Pharma. With a high-potential therapeutic segment and pricing advantage, the company appears well-positioned to capitalise on India’s expanding diabetes and obesity treatment market.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Feb 25, 2026, 11:54 AM IST
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
